Summary Exiqon A/S (Exiqon) is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company offers RNA, microRNA and LNA oligos products. Its RNA products comprise isolation, ISH, GapmeRs, qPCR and microarray systems. Exiqon offers LNA oligo products such as LNA oligo shop and LNA design tools. The company also provides RNA sequencing, microRNA PCR services, online RNA sequencing data analysis, RNA isolation, custom pharma and array services. It offers its gene expression analysis products for the life sciences industry and cellular based diagnostic tests for the diagnostics industry. Exiqon is headquartered in Vedbaek, Denmark. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company Exiqon AS - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons To Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Exiqon A/S Company Snapshot 6 Exiqon A/S Company Overview 6 Exiqon A/S Pipeline Products and Clinical Trials Overview 7 Exiqon A/S- Pipeline Analysis Overview 9 Key Facts 9 Exiqon A/S - Major Products and Services 10 Exiqon A/S Pipeline Products by Development Stage 11 Exiqon A/S Pipeline Products Overview 13 Colon Cancer Test - Stage III Patient 13 Colon Cancer Test - Stage III Patient Product Overview 13 Colon Cancer Test - Stage IV Patient 14 Colon Cancer Test - Stage IV Patient Product Overview 14 Diagnostic Test - Prostate Cancer Stratification 15 Diagnostic Test - Prostate Cancer Stratification Product Overview 15 Diagnostic Test - T-Cell Lymphoma 16 Diagnostic Test - T-Cell Lymphoma Product Overview 16 Genetic Test - Prostate Cancer 17 Genetic Test - Prostate Cancer Product Overview 17 miRNA Biomarker - Cancer of Unknown Primary 18 miRNA Biomarker - Cancer of Unknown Primary Product Overview 18 miRNA Test - Endometrial Cancer 19 miRNA Test - Endometrial Cancer Product Overview 19 miRNA Test - Lung Cancer 20 miRNA Test - Lung Cancer Product Overview 20 miRNA test-Ovarian 21 miRNA test-Ovarian Product Overview 21 miRNAbiomarker - Breast cancer 22 miRNAbiomarker - Breast cancer Product Overview 22 Prognosis Test - Prostate Cancer 23 Prognosis Test - Prostate Cancer Product Overview 23 Prostate Cancer - Early Detection Test 24 Prostate Cancer - Early Detection Test Product Overview 24 Prostate Cancer - Treatment Selection Test 25 Prostate Cancer - Treatment Selection Test Product Overview 25 Ran Biomarker Diagnostic Test 26 Ran Biomarker Diagnostic Test Product Overview 26 Exiqon A/S - Key Competitors 27 Exiqon A/S - Key Employees 28 Exiqon A/S - Locations And Subsidiaries 29 Head Office 29 Other Locations & Subsidiaries 29 Recent Developments 30 Exiqon A/S, Recent Developments 30 Apr 26, 2016: Exiqon: First Quarter 2016 Supports Continued Strong Momentum 30 Feb 08, 2016: Exiqon realizes full year 2015 profitability driven by strong revenue growth 30 Nov 06, 2015: Accelerated RNA discovery by XploreRNA presented to audience at Genome Festival 31 Oct 26, 2015: Third consecutive profitable quarter with continued strong growth 31 Aug 25, 2015: Exiqon: Continued strong performance in the second quarter with 24% growth and profitability 32 Jun 30, 2015: Exiqon integrates RNAseq workflow in unique cloud-computing environment, XploreRNA 33 Jun 30, 2015: Exiqon launches ExiLERATE LNA qPCR product portfolio for analysis of mRNA and lncRNA 33 Dec 18, 2014: Exiqon launches new Research Use Only kit for PCR analysis of colon cancer samples 34 Dec 18, 2014: Exiqon launches new Research Use Only kit miRSIGN miR-21 Oncogene assay 34 May 07, 2014: Exiqon Announces Interim Report For The Period 1 January - 31 March 2014 34 Appendix 36 Methodology 36 About GlobalData 36 Contact Us 36 Disclaimer 36
List of Tables
Exiqon A/S Pipeline Products and Clinical Trials Overview 7 Exiqon A/S Pipeline Products by Equipment Type 7 Exiqon A/S Pipeline Products by Indication 8 Exiqon A/S, Key Facts 9 Exiqon A/S, Major Products and Services 10 Exiqon A/S Number of Pipeline Products by Development Stage 11 Exiqon A/S Pipeline Products Summary by Development Stage 12 Colon Cancer Test - Stage III Patient - Product Status 13 Colon Cancer Test - Stage III Patient - Product Description 13 Colon Cancer Test - Stage IV Patient - Product Status 14 Colon Cancer Test - Stage IV Patient - Product Description 14 Diagnostic Test - Prostate Cancer Stratification - Product Status 15 Diagnostic Test - Prostate Cancer Stratification - Product Description 15 Diagnostic Test - T-Cell Lymphoma - Product Status 16 Diagnostic Test - T-Cell Lymphoma - Product Description 16 Genetic Test - Prostate Cancer - Product Status 17 Genetic Test - Prostate Cancer - Product Description 17 miRNA Biomarker - Cancer of Unknown Primary - Product Status 18 miRNA Biomarker - Cancer of Unknown Primary - Product Description 18 miRNA Test - Endometrial Cancer - Product Status 19 miRNA Test - Endometrial Cancer - Product Description 19 miRNA Test - Lung Cancer - Product Status 20 miRNA Test - Lung Cancer - Product Description 20 miRNA test-Ovarian - Product Status 21 miRNA test-Ovarian - Product Description 21 miRNAbiomarker - Breast cancer - Product Status 22 miRNAbiomarker - Breast cancer - Product Description 22 Prognosis Test - Prostate Cancer - Product Status 23 Prognosis Test - Prostate Cancer - Product Description 23 Prostate Cancer - Early Detection Test - Product Status 24 Prostate Cancer - Early Detection Test - Product Description 24 Prostate Cancer - Treatment Selection Test - Product Status 25 Prostate Cancer - Treatment Selection Test - Product Description 25 Ran Biomarker Diagnostic Test - Product Status 26 Ran Biomarker Diagnostic Test - Product Description 26 Exiqon A/S, Key Employees 28 Exiqon A/S, Subsidiaries 29
List of Figures
Exiqon A/S Pipeline Products by Equipment Type 8 Exiqon A/S Pipeline Products by Development Stage 11
Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries sRead More...
Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certainRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.